Revisiting the Association of Pesticide Exposure and Parkinson's Disease: Systematic Review and Meta-Analysis.

Environ ToxicolJan 21, 2026 (epub)
Clinical ResearchNeurologyOpen access

Pedro Henrique Passos da Silva, Jadson Silva Abreu, Rafael Sidônio Gibson Gomes et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis updated evidence on pesticide exposure and Parkinson’s disease (PD), examining associations by exposure type and pesticide class. The review included 124 eligible studies identified through searches of PubMed, EMBASE, and Web of Science through July 2024. Across studies considering any exposure, pesticide exposure overall and herbicide exposure were positively associated with PD. Occupational exposure was associated with PD for pesticide classes other than fungicides, and exclusive household exposure was also associated. The authors identified herbicides as having the strongest evidence of association.

Key findings

  • Among studies assessing any exposure, pesticide exposure overall and herbicide exposure were positively associated with PD.
  • Occupational exposure was associated with PD for all pesticide classes except fungicides.
  • Exclusive household pesticide exposure was also associated with PD.

Why it matters

The findings reinforce pesticide exposure as an environmental factor associated with PD and suggest that exposure context and pesticide class matter when interpreting the evidence. The review also highlights substantial methodological variability and limited population diversity, which constrain how confidently these associations can be generalized and point to priorities for future research.

What to keep in mind

The included studies showed high methodological variability, and the populations represented lacked diversity.

Source

Published in Environ Toxicol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.